ArticleScientific reports2025

Cost effectiveness of first line nivolumab plus bevacizumab and chemotherapy for advanced non squamous non small cell lung cancer.

Shan Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.